Expression analysis of Akirin-2, NFκB-p65 and β-catenin proteins in imatinib resistance of chronic myeloid leukemia.

Arzu Zeynep KarabayAsli KocTulin OzkanYalda HekmatshoarBuket Altinok GunesAsuman SungurogluZeliha BuyukbingolArzu AtalayFugen Aktan

Published in: Hematology (Amsterdam, Netherlands) (2018)

We show for the first time that Akirin-2 can be a novel biomarker in imatinib resistance. Targeting Akirin-2, NFκB and β-catenin genes may provide an opportunity to overcome imatinib resistance in CML.

Keyphrases

chronic myeloid leukemia
signaling pathway
epithelial mesenchymal transition
cell proliferation
lps induced
pi k akt
nuclear factor
genome wide
gene expression
cancer therapy
drug delivery
genome wide analysis